Outcome of patients with septic shock and high-dose vasopressor therapy

Abstract

BACKGROUND: Despite the dissemination of international guidelines, mortality from septic shock remains high. Norepinephrine is recommended as first-line vasopressor therapy with a target mean arterial pressure of 65 mmHg. High-dose vasopressor (HDV) may also be required. This study aimed to assess survival in patients with septic shock requiring HDV. We conducted a retrospective study of patients admitted between January 2008 and December 2013 to a 13-bed ICU for septic shock and receiving high-dose vasopressor therapy (defined by a dose >1 µg/kg/min). Primary outcome was 28-day mortality (D28). Secondary outcomes were 90-day mortality (D90), organ failure score (SOFA), duration of organ failure, duration and dosage of vasopressor agent and ischemic complications. RESULTS: In our cohort of 106 patients, mortality reached 60.4% at D28 and 66.3% at D90. One in two patients died before D10. The weight-based mean dose of vasopressor (WMD) represented the best prognostic factor. Using a cutoff of 0.75 µg/kg/min, WMD was associated with mortality with a sensitivity of 73% and specificity of 74%. The mortality rate reached 86.4% when WMD was above the cutoff value and associated with a SOFA score >10. Digital or limb necrosis was documented in 6 patients (5.7%). CONCLUSIONS: In total, 40% of septic shock patients receiving high-dose vasopressor therapy survived at day 28 after admission. A WMD cutoff value of 0.75 µg/kg/min, associated with a >10 SOFA score, was a strong predictor of death. These results provide insights into outcome of refractory septic shock, showing that administration of high-dose vasopressor may indeed be useful in these patients.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 29

1. 1.

   Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets. 2006;6(2):207-212.

   Not in our library10.2174/187153006777442332

2. 2.
   The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study · 2013

   No notice
3. 3.

   De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.

   Not in our library10.1056/nejmoa0907118

4. 4.

   Kimmoun A, Ducrocq N, Levy B. Mechanisms of vascular hyporesponsiveness in septic shock. Curr Vasc Pharmacol. 2013;11(2):139-149.

   Not in our library

5. 5.

   Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving S. Sepsis Campaign Guidelines Committee including The Pediatric: surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

   Not in our library10.1007/s00134-012-2769-8

6. 6.

   Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Herve F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583-1593.

   Not in our library10.1056/nejmoa1312173

7. 7.

   LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28(8):2729-2732.

   Not in our library10.1097/00003246-200008000-00007

8. 8.

   Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med. 2012;27(3):172-178.

   Not in our library10.1177/0885066610396312

9. 9.
   Early versus delayed administration of norepinephrine in patients with septic shock · 2014

   No notice
10. 10.

    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250-1256.

    Not in our library10.1097/01.ccm.0000050454.01978.3b

11. 11.

    Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving S. Sepsis Campaign Guidelines Committee including the Pediatric: surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.

    Not in our library10.1097/ccm.0b013e31827e83af

12. 12.

    Breslow MJ, Ligier B. Hyperadrenergic states. Crit Care Med. 1991;19(12):1566-1579.

    Not in our library10.1097/00003246-199112000-00021

13. 13.

    Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36(12):2019-2029.

    Not in our library10.1007/s00134-010-2045-8

14. 14.

    Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013;2013:654708.

    Not in our library10.1155/2013/654708

15. 15.

    Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R, Miller RR, Hirshberg EL, Grissom CK, Morris AH. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143(3):664-671.

    Not in our library10.1378/chest.12-1106

16. 16.

    Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, Meyssignac B, Vigne C, Zieleskiewicz L, Leone M. Norepinephrine: not too much. Too Long. Shock. 2015;44(4):305-309.

    Not in our library10.1097/shk.0000000000000426

17. 17.

    Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart Lung. 2011;40(3):247-252.

    Not in our library10.1016/j.hrtlng.2010.04.007

18. 18.

    Dopp-Zemel D, Groeneveld AB. High-dose norepinephrine treatment: determinants of mortality and futility in critically ill patients. Am J Crit Care. 2013;22(1):22-32.

    Not in our library10.4037/ajcc2013748

19. 19.

    Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care. 2009;37(2):286-289.

    Not in our library10.1177/0310057x0903700212

20. 20.

    Sprung CL, Cohen SL, Sjokvist P, Baras M, Bulow HH, Hovilehto S, Ledoux D, Lippert A, Maia P, Phelan D, Schobersberger W, Wennberg E, Woodcock T. End-of-life practices in European intensive care units: the Ethicus Study. JAMA. 2003;290(6):790-797.

    Not in our library10.1001/jama.290.6.790

21. 21.

    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.

    Not in our library10.1097/01.ccm.0000298158.12101.41

22. 22.

    Kastrup M, Braun J, Kaffarnik M, von Dossow-Hanfstingl V, Ahlborn R, Wernecke KD, Spies C. Catecholamine dosing and survival in adult intensive care unit patients. World J Surg. 2013;37(4):766-773.

    Not in our library10.1007/s00268-013-1926-8

23. 23.

    Sviri S, Hashoul J, Stav I, van Heerden PV. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care. 2014;29(1):157-160.

    Not in our library10.1016/j.jcrc.2013.09.004

24. 24.

    Katsaragakis S, Kapralou A, Theodorou D, Markogiannakis H, Larentzakis A, Stamou KM, Drimousis P, Bramis I. Refractory septic shock: efficacy and safety of very high doses of norepinephrine. Methods Find Exp Clin Pharmacol. 2006;28(5):307-313.

    Not in our library10.1358/mf.2006.28.5.990203

25. 25.

    Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock. 2004;22(4):314-319.

    Not in our library10.1097/01.shk.0000136097.42048.bd

26. 26.

    Miller JT, Welage LS, Kraft MD, Alaniz C. Does body weight impact the efficacy of vasopressin therapy in the management of septic shock? J Crit Care. 2012;27(3):289-293.

    Not in our library10.1016/j.jcrc.2011.06.018

27. 27.

    Abboud I, Lerolle N, Urien S, Tadie JM, Leviel F, Fagon JY, Faisy C. Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. Crit Care. 2009;13(4):R120.

    Not in our library10.1186/cc7972

28. 28.

    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.

    Not in our library10.1007/bf01709751

29. 29.

    Abid O, Akca S, Haji-Michael P, Vincent JL. Strong vasopressor support may be futile in the intensive care unit patient with multiple organ failure. Crit Care Med. 2000;28(4):947-949.

    Not in our library10.1097/00003246-200004000-00006

Cited by papers we hold 2

• Vasoplegia treatments: the past, the present, and the future · 2018
  No notice
• Mean arterial pressure and mortality in patients with distributive shock: a retrospective analysis of the MIMIC-III database · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.